{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:01:53Z","timestamp":1791151313430,"version":"4.1.0"},"reference-count":130,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2,15]]},"abstract":"<jats:p>T-cell non-Hodgkin lymphomas (NHLs) are uncommon malignancies. The current WHO\/EORTC classification recognizes 9 distinct clinicopathologic peripheral T-cell NHLs. These disorders have unique characteristics and require individualized diagnostic and therapeutic strategies. Tremendous progress has been made in recent years in the understanding of the pathogenesis of these disorders. Specific chromosomal translocations and viral infections are now known to be associated with certain lymphomas. In this review, we describe their clinical and pathologic features. We also discuss the use of molecular studies in the diagnostic work-up of T-cell lymphomas. Because of the rarity of these disorders and the lack of well-designed clinical trials, the treatment of peripheral T-cell NHLs is often challenging. Additional studies are required to learn more about the biology of these diseases, which may lead to more optimal and possibly targeted therapies.<\/jats:p>","DOI":"10.1182\/blood-2005-03-1306","type":"journal-article","created":{"date-parts":[[2005,10,6]],"date-time":"2005-10-06T20:14:12Z","timestamp":1128629652000},"page":"1255-1264","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":181,"title":["T-cell non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"107","author":[{"given":"Mujahid A.","family":"Rizvi","sequence":"first","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine, and the Division of Hematopathology, Department of Pathology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine, and the Division of Hematopathology, Department of Pathology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine, and the Division of Hematopathology, Department of Pathology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly P.","family":"Nelson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine, and the Division of Hematopathology, Department of Pathology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine, and the Division of Hematopathology, Department of Pathology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111900234553900_REF1","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89: 3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"2019111900234553900_REF2","doi-asserted-by":"crossref","unstructured":"Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13: 140-149.","DOI":"10.1093\/annonc\/mdf033"},{"key":"2019111900234553900_REF3","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol. 1999;10: 1419-1432.","DOI":"10.1023\/A:1008375931236"},{"key":"2019111900234553900_REF4","doi-asserted-by":"crossref","unstructured":"Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105: 3768-3785.","DOI":"10.1182\/blood-2004-09-3502"},{"key":"2019111900234553900_REF5","doi-asserted-by":"crossref","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77: 7415-7419.","DOI":"10.1073\/pnas.77.12.7415"},{"key":"2019111900234553900_REF6","doi-asserted-by":"crossref","unstructured":"Takatsuki K, Matsuoka M, Yamaguchi K. Adult T-cell leukemia in Japan. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(suppl 1): S15-S19.","DOI":"10.1097\/00042560-199600001-00004"},{"key":"2019111900234553900_REF7","doi-asserted-by":"crossref","unstructured":"Taylor GP. The epidemiology of HTLV-I in Europe. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(suppl 1): S8-S14.","DOI":"10.1097\/00042560-199600001-00003"},{"key":"2019111900234553900_REF8","doi-asserted-by":"crossref","unstructured":"Chen YC, Wang CH, Su IJ, et al. Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion. Blood. 1989;74: 388-394.","DOI":"10.1182\/blood.V74.1.388.388"},{"key":"2019111900234553900_REF9","doi-asserted-by":"crossref","unstructured":"Pagliuca A. Strongyloides hyperinfection in adult T-cell leukaemia\/lymphoma [abstract]. Br J Haematol. 1999;105: 1.","DOI":"10.1111\/j.1365-2141.1999.01401.x"},{"key":"2019111900234553900_REF10","doi-asserted-by":"crossref","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79: 428-437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"2019111900234553900_REF11","doi-asserted-by":"crossref","unstructured":"Franchini G. Molecular mechanisms of human T-cell leukemia\/lymphotropic virus type I infection. Blood. 1995;86: 3619-3639.","DOI":"10.1182\/blood.V86.10.3619.bloodjournal86103619"},{"key":"2019111900234553900_REF12","doi-asserted-by":"crossref","unstructured":"Evens AM, Gartenhaus RB. Molecular etiology of mature T-cell non-Hodgkin's lymphomas. Front Biosci. 2003;8: d156-d175.","DOI":"10.2741\/922"},{"key":"2019111900234553900_REF13","doi-asserted-by":"crossref","unstructured":"Itoyama T, Chaganti RS, Yamada Y, et al. Cytogenetic analysis and clinical significance in adult T-cell leukemia\/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood. 2001;97: 3612-3620.","DOI":"10.1182\/blood.V97.11.3612"},{"key":"2019111900234553900_REF14","doi-asserted-by":"crossref","unstructured":"Tsukasaki K, Krebs J, Nagai K, et al. Comparative genomic hybridization analysis in adult T-cell leukemia\/lymphoma: correlation with clinical course. Blood. 2001;97: 3875-3881.","DOI":"10.1182\/blood.V97.12.3875"},{"key":"2019111900234553900_REF15","doi-asserted-by":"crossref","unstructured":"Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood. 1997;89: 948-956.","DOI":"10.1182\/blood.V89.3.948"},{"key":"2019111900234553900_REF16","doi-asserted-by":"crossref","unstructured":"Ohshima K, Mukai Y, Shiraki H, Suzumiya J, Tashiro K, Kikuchi M. Clonal integration and expression of human T-cell lymphotropic virus type I in carriers detected by polymerase chain reaction and inverse PCR. Am J Hematol. 1997;54: 306-312.","DOI":"10.1002\/(SICI)1096-8652(199704)54:4<306::AID-AJH8>3.0.CO;2-Z"},{"key":"2019111900234553900_REF17","doi-asserted-by":"crossref","unstructured":"Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol. 2001;113: 779-784.","DOI":"10.1046\/j.1365-2141.2001.02794.x"},{"key":"2019111900234553900_REF18","doi-asserted-by":"crossref","unstructured":"Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma. Hematol J. 2002;3: 276-282.","DOI":"10.1038\/sj.thj.6200195"},{"key":"2019111900234553900_REF19","doi-asserted-by":"crossref","unstructured":"Besson C, Panelatti G, Delaunay C, et al. Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk Lymphoma. 2002;43: 2275-2279.","DOI":"10.1080\/1042819021000039983"},{"key":"2019111900234553900_REF20","unstructured":"El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000;96: 2849-2855."},{"key":"2019111900234553900_REF21","doi-asserted-by":"crossref","unstructured":"Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93: 278-283.","DOI":"10.1182\/blood.V93.1.278"},{"key":"2019111900234553900_REF22","doi-asserted-by":"crossref","unstructured":"Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic\/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 2003;101: 4576-4582.","DOI":"10.1182\/blood-2002-09-2986"},{"key":"2019111900234553900_REF23","unstructured":"Dierov J, Sawaya BE, Prosniak M, Gartenhaus RB. Retinoic acid modulates a bimodal effect on cell cycle progression in human adult T-cell leukemia cells. Clin Cancer Res. 1999;5: 2540-2547."},{"key":"2019111900234553900_REF24","doi-asserted-by":"crossref","unstructured":"Nasr R, El-Sabban M, Karam J, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia\/lymphoma. Oncogene. 2005;24: 419-430.","DOI":"10.1038\/sj.onc.1208212"},{"key":"2019111900234553900_REF25","doi-asserted-by":"crossref","unstructured":"Sonnen R, Schmidt W, Muller-Hermelink H, et al. The international prognostic index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol. 2005;129: 366-372.","DOI":"10.1111\/j.1365-2141.2005.05478.x"},{"key":"2019111900234553900_REF26","doi-asserted-by":"crossref","unstructured":"Theodorou I, Bigorgne C, Delfau MH, et al. VJ rearrangements of the TCR gamma locus in peripheral T-cell lymphomas: analysis by polymerase chain reaction and denaturing gradient gel electrophoresis. J Pathol. 1996;178: 303-310.","DOI":"10.1002\/(SICI)1096-9896(199603)178:3<303::AID-PATH475>3.0.CO;2-I"},{"key":"2019111900234553900_REF27","doi-asserted-by":"crossref","unstructured":"Theodorou I, Raphael M, Bigorgne C, et al. Recombination pattern of the TCR gamma locus in human peripheral T-cell lymphomas. J Pathol. 1994;174: 233-242.","DOI":"10.1002\/path.1711740402"},{"key":"2019111900234553900_REF28","doi-asserted-by":"crossref","unstructured":"Lepretre S, Buchonnet G, Stamatoullas A, et al. Chromosome abnormalities in peripheral T-cell lymphoma. Cancer Genet Cytogenet. 2000;117: 71-79.","DOI":"10.1016\/S0165-4608(99)00151-X"},{"key":"2019111900234553900_REF29","doi-asserted-by":"crossref","unstructured":"Schlegelberger B, Feller AC. Classification of peripheral T-cell lymphomas: cytogenetic findings support the updated Kiel classification. Leuk Lymphoma. 1996;20: 411-416.","DOI":"10.3109\/10428199609052422"},{"key":"2019111900234553900_REF30","doi-asserted-by":"crossref","unstructured":"Hoshida Y, Hongyo T, Nakatsuka S, et al. Gene mutations in lymphoproliferative disorders of T and NK\/T cell phenotypes developing in renal transplant patients. Lab Invest. 2002;82: 257-264.","DOI":"10.1038\/labinvest.3780419"},{"key":"2019111900234553900_REF31","doi-asserted-by":"crossref","unstructured":"Pescarmona E, Pignoloni P, Puopolo M, et al. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol. 2001;195: 361-366.","DOI":"10.1002\/path.945"},{"key":"2019111900234553900_","unstructured":"Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5: 1085-1091."},{"key":"2019111900234553900_REF33","unstructured":"Kanavaros P, Bai M, Stefanaki K, et al. Immunohistochemical expression of the p53, mdm2, p21\/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas. Histol Histopathol. 2001;16: 377-386."},{"key":"2019111900234553900_REF34","doi-asserted-by":"crossref","unstructured":"Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992;327: 1342-1349.","DOI":"10.1056\/NEJM199211053271903"},{"key":"2019111900234553900_REF35","doi-asserted-by":"crossref","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 1002-1006.","DOI":"10.1056\/NEJM199304083281404"},{"key":"2019111900234553900_REF36","doi-asserted-by":"crossref","unstructured":"Kurzrock R. Therapy of T cell lymphomas with pentostatin. Ann N Y Acad Sci. 2001;941: 200-205.","DOI":"10.1111\/j.1749-6632.2001.tb03724.x"},{"key":"2019111900234553900_REF37","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer. 2004;100: 342-349.","DOI":"10.1002\/cncr.11899"},{"key":"2019111900234553900_","doi-asserted-by":"crossref","unstructured":"Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994;12: 2588-2593.","DOI":"10.1200\/JCO.1994.12.12.2588"},{"key":"2019111900234553900_REF39","doi-asserted-by":"crossref","unstructured":"Monfardini S, Sorio R, Cavalli F, et al. Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. Oncology. 1996;53: 163-168.","DOI":"10.1159\/000227554"},{"key":"2019111900234553900_REF40","doi-asserted-by":"crossref","unstructured":"Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113: 185-187.","DOI":"10.1046\/j.1365-2141.2001.02743.x"},{"key":"2019111900234553900_REF41","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998; 9: 1351-1353.","DOI":"10.1023\/A:1008409601731"},{"key":"2019111900234553900_REF42","unstructured":"LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998;91: 399-405."},{"key":"2019111900234553900_REF43","doi-asserted-by":"crossref","unstructured":"Talpur R, Apisarnthanarax N, Ward S, Duvic M. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma. 2002;43: 121-126.","DOI":"10.1080\/10428190210183"},{"key":"2019111900234553900_REF44","doi-asserted-by":"crossref","unstructured":"Dang N, Pro B, Hagemeister FB, et al. Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapsed\/refractory T-cell non-Hodgkin's lymphoma [abstract]. Blood. 2004;104: 722.","DOI":"10.1182\/blood.V104.11.2641.2641"},{"key":"2019111900234553900_REF45","doi-asserted-by":"crossref","unstructured":"Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103: 2920-2924.","DOI":"10.1182\/blood-2003-10-3389"},{"key":"2019111900234553900_REF46","doi-asserted-by":"crossref","unstructured":"Siegert W, Nerl C, Agthe A, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation: the Kiel Lymphoma Study Group. Ann Oncol. 1995;6: 659-664.","DOI":"10.1093\/oxfordjournals.annonc.a059281"},{"key":"2019111900234553900_REF47","unstructured":"Feller AC, Griesser H, Schilling CV, et al. Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol. 1988;133: 549-556."},{"key":"2019111900234553900_REF48","doi-asserted-by":"crossref","unstructured":"Lipford EH, Smith HR, Pittaluga S, Jaffe ES, Steinberg AD, Cossman J. Clonality of angioimmunoblastic lymphadenopathy and implications for its evolution to malignant lymphoma. J Clin Invest. 1987;79: 637-642.","DOI":"10.1172\/JCI112860"},{"key":"2019111900234553900_REF49","doi-asserted-by":"crossref","unstructured":"Schlegelberger B, Zhang Y, Weber-Matthiesen K, Grote W. Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics. Blood. 1994;84: 2640-2648.","DOI":"10.1182\/blood.V84.8.2640.2640"},{"key":"2019111900234553900_REF50","doi-asserted-by":"crossref","unstructured":"Schlegelberger B, Zwingers T, Hohenadel K, et al. Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. J Clin Oncol. 1996;14: 593-599.","DOI":"10.1200\/JCO.1996.14.2.593"},{"key":"2019111900234553900_REF51","doi-asserted-by":"crossref","unstructured":"Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood. 1992;80: 1804-1812.","DOI":"10.1182\/blood.V80.7.1804.1804"},{"key":"2019111900234553900_REF52","doi-asserted-by":"crossref","unstructured":"Brauninger A, Spieker T, Willenbrock K, et al. Survival and clonal expansion of mutating \u201cforbidden\u201d (immunoglobulin receptor-deficient) Epstein-Barr virus-infected B cells in angioimmunoblastic T cell lymphoma. J Exp Med. 2001;194: 927-940.","DOI":"10.1084\/jem.194.7.927"},{"key":"2019111900234553900_REF53","doi-asserted-by":"crossref","unstructured":"Sallah S, Gagnon GA. Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment. Acta Haematol. 1998;99: 57-64.","DOI":"10.1159\/000040811"},{"key":"2019111900234553900_REF54","doi-asserted-by":"crossref","unstructured":"Reiser M, Josting A, Soltani M, et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma. 2002;43: 805-811.","DOI":"10.1080\/10428190290016926"},{"key":"2019111900234553900_REF55","doi-asserted-by":"crossref","unstructured":"Siegert W, Agthe A, Griesser H, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM\/IMVP-16 regimen: a multicenter study: Kiel Lymphoma Study Group. Ann Intern Med. 1992;117: 364-370.","DOI":"10.7326\/0003-4819-117-5-364"},{"key":"2019111900234553900_REF56","doi-asserted-by":"crossref","unstructured":"Quintini G, Iannitto E, Barbera V, et al. Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma. Hematol J. 2001; 2: 393-395.","DOI":"10.1038\/sj.thj.6200136"},{"key":"2019111900234553900_REF57","doi-asserted-by":"crossref","unstructured":"Tsatalas C, Margaritis D, Kaloutsi V, Martinis G, Kotsianidis I, Bourikas G. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. Acta Haematol. 2001;105: 106-108.","DOI":"10.1159\/000046545"},{"key":"2019111900234553900_REF58","doi-asserted-by":"crossref","unstructured":"Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood. 1997; 89: 4514-4520.","DOI":"10.1182\/blood.V89.12.4514"},{"key":"2019111900234553900_REF59","doi-asserted-by":"crossref","unstructured":"Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93: 3913-3921.","DOI":"10.1182\/blood.V93.11.3913"},{"key":"2019111900234553900_REF60","unstructured":"Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93: 2697-2706."},{"key":"2019111900234553900_REF61","unstructured":"Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype. Blood. 2000;96: 2993-3000."},{"key":"2019111900234553900_REF62","doi-asserted-by":"crossref","unstructured":"Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood. 1996;88: 4005-4011.","DOI":"10.1182\/blood.V88.10.4005.bloodjournal88104005"},{"key":"2019111900234553900_REF63","doi-asserted-by":"crossref","unstructured":"Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 1988;72: 234-240.","DOI":"10.1182\/blood.V72.1.234.234"},{"key":"2019111900234553900_REF64","doi-asserted-by":"crossref","unstructured":"Weisenburger DD, Gordon BG, Vose JM, et al. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma. Blood. 1996;87: 3860-3868.","DOI":"10.1182\/blood.V87.9.3860.bloodjournal8793860"},{"key":"2019111900234553900_REF65","doi-asserted-by":"crossref","unstructured":"Fujimoto J, Shiota M, Iwahara T, et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A. 1996;93: 4181-4186.","DOI":"10.1073\/pnas.93.9.4181"},{"key":"2019111900234553900_REF66","doi-asserted-by":"crossref","unstructured":"Lamant L, Meggetto F, al Saati T, et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease: comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood. 1996;87: 284-291.","DOI":"10.1182\/blood.V87.1.284.284"},{"key":"2019111900234553900_REF67","doi-asserted-by":"crossref","unstructured":"Mathew P, Sanger WG, Weisenburger DD, et al. Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. Blood. 1997; 89: 1678-1685.","DOI":"10.1182\/blood.V89.5.1678"},{"key":"2019111900234553900_REF68","doi-asserted-by":"crossref","unstructured":"Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89: 1394-1404.","DOI":"10.1182\/blood.V89.4.1394"},{"key":"2019111900234553900_REF69","unstructured":"Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood. 1999;94: 3509-3515."},{"key":"2019111900234553900_REF70","doi-asserted-by":"crossref","unstructured":"Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25; p23) translocation. Blood. 1999;93: 3088-3095.","DOI":"10.1182\/blood.V93.9.3088"},{"key":"2019111900234553900_REF71","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Ott G, Pulford K, et al. t(1;2)(q21; p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood. 1999;94: 362-364.","DOI":"10.1182\/blood.V94.1.362.413a45_362_364"},{"key":"2019111900234553900_REF72","doi-asserted-by":"crossref","unstructured":"Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood. 2000;95: 3204-3207.","DOI":"10.1182\/blood.V95.10.3204"},{"key":"2019111900234553900_REF73","unstructured":"Trinei M, Lanfrancone L, Campo E, et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 2000; 60: 793-798."},{"key":"2019111900234553900_REF74","doi-asserted-by":"crossref","unstructured":"Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96: 3681-3695.","DOI":"10.1182\/blood.V96.12.3681"},{"key":"2019111900234553900_REF75","doi-asserted-by":"crossref","unstructured":"ten Berge RL, Meijer CJ, Dukers DF, et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood. 2002;99: 4540-4546.","DOI":"10.1182\/blood.V99.12.4540"},{"key":"2019111900234553900_REF76","doi-asserted-by":"crossref","unstructured":"Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood. 1998;91: 2977-2984.","DOI":"10.1182\/blood.V91.8.2977.2977_2977_2984"},{"key":"2019111900234553900_REF77","doi-asserted-by":"crossref","unstructured":"Inghirami G, Macri L, Cesarman E, Chadburn A, Zhong J, Knowles DM. Molecular characterization of CD30+ anaplastic large-cell lymphoma: high frequency of c-myc proto-oncogene activation. Blood. 1994;83: 3581-3590.","DOI":"10.1182\/blood.V83.12.3581.3581"},{"key":"2019111900234553900_REF78","doi-asserted-by":"crossref","unstructured":"Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase\/Akt antiapoptotic signaling pathway. Blood. 2000;96: 4319-4327.","DOI":"10.1182\/blood.V96.13.4319"},{"key":"2019111900234553900_REF79","doi-asserted-by":"crossref","unstructured":"Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 2001;97: 3699-3706.","DOI":"10.1182\/blood.V97.12.3699"},{"key":"2019111900234553900_REF80","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Bendandi M, Martelli M, et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol. 1996;14: 955-962.","DOI":"10.1200\/JCO.1996.14.3.955"},{"key":"2019111900234553900_REF81","doi-asserted-by":"crossref","unstructured":"Su IJ, Wang CH, Cheng AL, Chen RL. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk Lymphoma. 1995;19: 401-406.","DOI":"10.3109\/10428199509112197"},{"key":"2019111900234553900_REF82","doi-asserted-by":"crossref","unstructured":"Marzano AV, Berti E, Paulli M, Caputo R. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol. 2000;136: 889-896.","DOI":"10.1001\/archderm.136.7.889"},{"key":"2019111900234553900_REF83","doi-asserted-by":"crossref","unstructured":"Craig AJ, Cualing H, Thomas G, Lamerson C, Smith R. Cytophagic histiocytic panniculitis\u2014a syndrome associated with benign and malignant panniculitis: case comparison and review of the literature. J Am Acad Dermatol. 1998;39: 721-736.","DOI":"10.1016\/S0190-9622(98)70044-1"},{"key":"2019111900234553900_REF84","doi-asserted-by":"crossref","unstructured":"Hoque SR, Child FJ, Whittaker SJ, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003;148: 516-525.","DOI":"10.1046\/j.1365-2133.2003.05226.x"},{"key":"2019111900234553900_REF85","unstructured":"Wick MR, Patterson JW. Cytophagic histiocytic panniculitis\u2014a critical reappraisal. Arch Dermatol. 2000;136: 922-924."},{"key":"2019111900234553900_REF86","doi-asserted-by":"crossref","unstructured":"Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha\/beta and gamma\/delta subtypes. Am J Surg Pathol. 1998;22: 881-893.","DOI":"10.1097\/00000478-199807000-00010"},{"key":"2019111900234553900_REF87","doi-asserted-by":"crossref","unstructured":"Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK\/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004;28: 719-735.","DOI":"10.1097\/01.pas.0000126719.71954.4f"},{"key":"2019111900234553900_REF88","unstructured":"Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al. Nonhepatosplenic \u03b3\u03b4 T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood. 1998;91: 1723-1731."},{"key":"2019111900234553900_REF89","doi-asserted-by":"crossref","unstructured":"Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101: 3407-3412.","DOI":"10.1182\/blood-2002-05-1597"},{"key":"2019111900234553900_REF90","doi-asserted-by":"crossref","unstructured":"Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic \u03b3\u03b4 T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102: 4261-4269.","DOI":"10.1182\/blood-2003-05-1675"},{"key":"2019111900234553900_REF91","doi-asserted-by":"crossref","unstructured":"Przybylski GK, Wu H, Macon WR, et al. Hepatosplenic and subcutaneous panniculitis-like gamma\/delta T cell lymphomas are derived from different Vdelta subsets of gamma\/delta T lymphocytes. J Mol Diagn. 2000;2: 11-19.","DOI":"10.1016\/S1525-1578(10)60610-1"},{"key":"2019111900234553900_REF92","doi-asserted-by":"crossref","unstructured":"Farcet JP, Gaulard P, Marolleau JP, et al. Hepatosplenic T-cell lymphoma: sinusal\/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood. 1990;75: 2213-2219.","DOI":"10.1182\/blood.V75.11.2213.2213"},{"key":"2019111900234553900_REF93","doi-asserted-by":"crossref","unstructured":"Suarez F, Wlodarska I, Rigal-Huguet F, et al. Hepatosplenic \u03b1\u03b2 T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of \u03b3\u03b4 hepatosplenic T-cell lymphoma. Am J Surg Pathol. 2000;24: 1027-1032.","DOI":"10.1097\/00000478-200007000-00016"},{"key":"2019111900234553900_REF94","doi-asserted-by":"crossref","unstructured":"Iannitto E, Barbera V, Quintini G, Cirrincione S, Leone M. Hepatosplenic \u03b3\u03b4 T-cell lymphoma: complete response induced by treatment with pentostatin. Br J Haematol. 2002;117: 995-996.","DOI":"10.1046\/j.1365-2141.2002.03537_3.x"},{"key":"2019111900234553900_REF95","doi-asserted-by":"crossref","unstructured":"Chanan-Khan A, Islam T, Alam A, et al. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha\/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2004;45: 1673-1675.","DOI":"10.1080\/10428190310001609924"},{"key":"2019111900234553900_REF96","doi-asserted-by":"crossref","unstructured":"Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T\/Natural Killer Cell Lymphomas: definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20: 103-111.","DOI":"10.1097\/00000478-199601000-00012"},{"key":"2019111900234553900_REF97","doi-asserted-by":"crossref","unstructured":"Kim GE, Lee SW, Chang SK, et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol. 2001;61: 261-269.","DOI":"10.1016\/S0167-8140(01)00428-5"},{"key":"2019111900234553900_REF98","doi-asserted-by":"crossref","unstructured":"Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16: 70-77.","DOI":"10.1200\/JCO.1998.16.1.70"},{"key":"2019111900234553900_REF99","doi-asserted-by":"crossref","unstructured":"Quintanilla-Martinez L, Franklin JL, Guerrero I, et al. Histological and immunophenotypic profile of nasal NK\/T cell lymphomas from Peru: high prevalence of p53 overexpression. Hum Pathol. 1999;30: 849-855.","DOI":"10.1016\/S0046-8177(99)90147-8"},{"key":"2019111900234553900_REF100","doi-asserted-by":"crossref","unstructured":"Ko YH, Ree HJ, Kim WS, Choi WH, Moon WS, Kim SW. Clinicopathologic and genotypic study of extranodal nasal-type natural killer\/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer. 2000;89: 2106-2116.","DOI":"10.1002\/1097-0142(20001115)89:10<2106::AID-CNCR11>3.0.CO;2-G"},{"key":"2019111900234553900_REF101","doi-asserted-by":"crossref","unstructured":"Chiang AK, Chan AC, Srivastava G, Ho FC. Nasal T\/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int J Cancer. 1997;73: 332-338.","DOI":"10.1002\/(SICI)1097-0215(19971104)73:3<332::AID-IJC5>3.0.CO;2-0"},{"key":"2019111900234553900_REF102","doi-asserted-by":"crossref","unstructured":"Siu LL, Wong KF, Chan JK, Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma\/leukemia: recognition of consistent patterns of genetic alterations. Am J Pathol. 1999;155: 1419-1425.","DOI":"10.1016\/S0002-9440(10)65454-5"},{"key":"2019111900234553900_REF103","doi-asserted-by":"crossref","unstructured":"Sakajiri S, Kawamata N, Egashira M, Mori K, Oshimi K. Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms. Jpn J Cancer Res. 2001;92: 1048-1056.","DOI":"10.1111\/j.1349-7006.2001.tb01059.x"},{"key":"2019111900234553900_REF104","doi-asserted-by":"crossref","unstructured":"Kanavaros P, Lescs MC, Briere J, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood. 1993;81: 2688-2695.","DOI":"10.1182\/blood.V81.10.2688.2688"},{"key":"2019111900234553900_REF105","doi-asserted-by":"crossref","unstructured":"Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18: 54-63.","DOI":"10.1200\/JCO.2000.18.1.54"},{"key":"2019111900234553900_REF106","doi-asserted-by":"crossref","unstructured":"Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer\/T-cell or T-cell lymphoma. Cancer. 2004;100: 366-375.","DOI":"10.1002\/cncr.11908"},{"key":"2019111900234553900_REF107","doi-asserted-by":"crossref","unstructured":"Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer. 1998;83: 449-456.","DOI":"10.1002\/(SICI)1097-0142(19980801)83:3<449::AID-CNCR13>3.0.CO;2-W"},{"key":"2019111900234553900_REF108","doi-asserted-by":"crossref","unstructured":"Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18: 795-803.","DOI":"10.1200\/JCO.2000.18.4.795"},{"key":"2019111900234553900_REF109","doi-asserted-by":"crossref","unstructured":"Howell WM, Leung ST, Jones DB, et al. HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma: common features and additional risk factors for malignancy. Hum Immunol. 1995;43: 29-37.","DOI":"10.1016\/0198-8859(94)00130-I"},{"key":"2019111900234553900_REF110","unstructured":"Murray A, Cuevas EC, Jones DB, Wright DH. Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma. Am J Pathol. 1995;146: 509-519."},{"key":"2019111900234553900_REF111","doi-asserted-by":"crossref","unstructured":"Daum S, Weiss D, Hummel M, et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut. 2001; 49: 804-812.","DOI":"10.1136\/gut.49.6.804"},{"key":"2019111900234553900_REF112","doi-asserted-by":"crossref","unstructured":"Obermann EC, Diss TC, Hamoudi RA, et al. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma. J Pathol. 2004;202: 252-262.","DOI":"10.1002\/path.1506"},{"key":"2019111900234553900_REF113","unstructured":"Abe Y, Muta K, Ohshima K, et al. Cytotoxic T-cell lymphoma diffusely involving the entire gastrointestinal tract associated with Epstein-Barr virus and tubercle bacilli infection. Int J Hematol. 2000; 71: 379-384."},{"key":"2019111900234553900_REF114","doi-asserted-by":"crossref","unstructured":"Quintanilla-Martinez L, Lome-Maldonado C, Ott G, et al. Primary non-Hodgkin's lymphoma of the intestine: high prevalence of Epstein-Barr virus in Mexican lymphomas as compared with European cases. Blood. 1997;89: 644-651.","DOI":"10.1182\/blood.V89.2.644"},{"key":"2019111900234553900_REF115","doi-asserted-by":"crossref","unstructured":"Blystad AK, Enblad G, Kvaloy S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27: 711-716.","DOI":"10.1038\/sj.bmt.1702867"},{"key":"2019111900234553900_REF116","doi-asserted-by":"crossref","unstructured":"Kahl C, Leithauser M, Wolff D, et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol. 2002;81: 646-650.","DOI":"10.1007\/s00277-002-0556-2"},{"key":"2019111900234553900_REF117","doi-asserted-by":"crossref","unstructured":"Rodriguez J, Munsell M, Yazji S, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001;19: 3766-3770.","DOI":"10.1200\/JCO.2001.19.17.3766"},{"key":"2019111900234553900_REF118","doi-asserted-by":"crossref","unstructured":"Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120: 978-985.","DOI":"10.1046\/j.1365-2141.2003.04203.x"},{"key":"2019111900234553900_","doi-asserted-by":"crossref","unstructured":"Rodriguez J, Caballero MD, Gutierrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14: 1768-1775.","DOI":"10.1093\/annonc\/mdg459"},{"key":"2019111900234553900_REF120","doi-asserted-by":"crossref","unstructured":"Jantunen E, Wiklund T, Juvonen E, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33: 405-410.","DOI":"10.1038\/sj.bmt.1704367"},{"key":"2019111900234553900_REF121","unstructured":"Rodriguez J, Caballero MD, Gutierrez A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy: the GEL-TAMO experience. Haematologica. 2003;88: 1372-1377."},{"key":"2019111900234553900_REF122","doi-asserted-by":"crossref","unstructured":"Deconinck E, Lamy T, Foussard C, et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol. 2000;109: 736-742.","DOI":"10.1046\/j.1365-2141.2000.02098.x"},{"key":"2019111900234553900_REF123","doi-asserted-by":"crossref","unstructured":"Fanin R, Sperotto A, Silvestri F, et al. The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. Leuk Lymphoma. 1999; 35: 159-169.","DOI":"10.3109\/10428199909145715"},{"key":"2019111900234553900_REF124","doi-asserted-by":"crossref","unstructured":"Imashuku S, Hibi S, Todo S, et al. Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan. Bone Marrow Transplant. 1999;23: 569-572.","DOI":"10.1038\/sj.bmt.1701620"},{"key":"2019111900234553900_REF125","doi-asserted-by":"crossref","unstructured":"Buttgereit P, Schakowski F, Marten A, et al. Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells. Cancer Gene Ther. 2001;8: 430-439.","DOI":"10.1038\/sj.cgt.7700323"},{"key":"2019111900234553900_REF126","unstructured":"Nagata S, Onda M, Numata Y, et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res. 2002;8: 2345-2355."},{"key":"2019111900234553900_REF127","doi-asserted-by":"crossref","unstructured":"Moura IC, Lepelletier Y, Arnulf B, et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood. 2004;103: 1838-1845.","DOI":"10.1182\/blood-2003-07-2440"},{"key":"2019111900234553900_REF128","doi-asserted-by":"crossref","unstructured":"Blackhall FH, Ranson M, Radford JA, et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer. 2001;84: 465-469.","DOI":"10.1054\/bjoc.2000.1624"},{"key":"2019111900234553900_REF129","unstructured":"Harvey S, Decker R, Dai Y, et al. Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. Clin Cancer Res. 2001; 7: 320-330."},{"key":"2019111900234553900_REF130","doi-asserted-by":"crossref","unstructured":"Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001;98: 2865-2868.","DOI":"10.1182\/blood.V98.9.2865"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/4\/1255\/468637\/zh800406001255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/4\/1255\/468637\/zh800406001255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T20:57:34Z","timestamp":1683233854000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/4\/1255\/133674\/Tcell-nonHodgkin-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,15]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-03-1306","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,15]]}}}